Xcopri (Cenobamate)

Save over 60% over US Xcopri prices with insulinhub.com.  Xcopri also goes by the name Ontozry in Europe.

Manufacturer Swiss Caps GmbH Grassingerstrasse 9 83043 Bad Aibling Germany

Information about Xcopri (Cenobamate)

Xcopri contains cenobamate, which works by inhibiting the abnormal electrical activity in the brain that causes seizures. It does so through a dual mechanism of action: reducing excitability by enhancing GABA (gamma-aminobutyric acid) activity and inhibiting sodium channels, which helps to stabilize the neuronal activity in the brain.

Product Highlights

• Xcopri is indicated for the treatment of partial-onset seizures in adults with epilepsy, whether they occur as simple or complex partial seizures.

Key Ingredient

• Cenobamate

Key Benefits

• Xcopri has been shown to significantly reduce the frequency of partial-onset seizures in patients with epilepsy.
• By targeting both GABA receptors and sodium channels, cenobamate offers a more comprehensive approach to managing seizures.
• In clinical trials, cenobamate was generally well-tolerated with a manageable side-effect profile.
• Xcopri comes in tablet form, which is easy to administer compared to other more complex treatments.

Direction of Use

• Xcopri is typically started at a low dose, which is gradually increased to minimize the risk of side effects. The typical starting dose is 12.5 mg daily, which can be increased in increments as prescribed by a doctor. The usual maintenance dose is between 100 mg and 200 mg daily, depending on patient tolerance and response.
• Take Xcopri orally with or without food. The tablet must be swallowed whole and not crushed or chewed. 
• If you miss a dose, take it as soon as you recall, unless it’s close to the time for your next dose. Do not take a double dose to make up for the missed one. 
• Regular follow-up visits with your healthcare provider are recommended to assess the effectiveness of the treatment and any potential side effects.

Safety Concerns

• Cenobamate can cause drowsiness, dizziness, or sedation, especially when starting treatment or increasing the dose. Patients should exercise caution when participating in activities that require focus, like driving. 
• Like other anticonvulsants, Xcopri may increase the risk of suicidal thoughts or behaviors. Patients should be monitored for any mood changes or thoughts of self-harm.
• Cenobamate may interact with other medications, particularly other anticonvulsants, sedatives, or medications affecting the central nervous system. Always inform your healthcare provider about all the medications you're taking.
• Stopping Xcopri suddenly can increase the risk of seizures. It should be tapered gradually under the supervision of a healthcare provider.
• Liver function should be monitored, as cenobamate may have an impact on liver enzymes in some individuals.

Avoid Xcopri (Cenobamate) If

• If you have a history of hypersensitivity or allergic reactions to cenobamate or any of its ingredients, you should avoid using this medication.
• Cenobamate is contraindicated in patients with severe liver impairment, as it may worsen liver function.
• Xcopri should only be used during pregnancy if absolutely necessary, as it may pose risks to the fetus. It should be avoided during breastfeeding unless advised by a doctor.
• If you are already taking certain anticonvulsant drugs, Xcopri may interact with them. Your healthcare provider will carefully manage these interactions.